



SPHINGOLIPID CLUB


NEUR+MED
I.R.C.C.S.
ISTITUTO
NEUROLOGICO
MEDITERRANEO

Fondazione
NEUR+MED

we are sphingolipids



14th SLC Meeting






14th SLC Meeting

Thursday, Sept. 8, 2022

Neuromed Research Centre, Pozzilli

- 09:00-09:05 *Welcome greetings*
Luigi Frati *Scientific Director IRCCS Neuromed*
Giovanni de Gaetano *President IRCCS Neuromed*
- 09:05-09:14 *Opening remarks*
Vittorio Maglione, Alba Di Pardo (IRCCS Neuromed, IT)
- 09:15-09:50 *Keynote Lecture*
Timothy Cox (University of Cambridge, UK)
Sphingolipids – classical matters in the ancient and modern world
- 09:50 -11:45 **SESSION 1**
Sphingolipids in health and disease (I)
Chairs: **Marco Presta** (Brescia, IT),
Carmen Garcia-Ruiz (Barcelona, ES)
- 09:50 - 10:15 **Lauren Ashley Cowart** (Virginia Commonwealth University, US)
Sptlc3 and novel sphingolipids in health and disease
- 10:15 -10:30 **Duyen Tran** (University of Tasmania, AU)
Toxic 1-deoxysphinganine, compromises the functionality of skeletal myoblasts and underlies the development of type 2 diabetes mellitus
- 10:30-10:45 **Anna Kovilakath** (Virginia Commonwealth University, US)
The novel sphingolipid enzyme SPTLC3 ameliorates ischemic failure by reducing reactive oxygen species
- 10:45 -11:00 **Marcelo Einicker-Lamas** (Universidade Federal do Rio de Janeiro, BR)
Sphingosine-1-phosphate prevents human embryonic stem cell death following ischemic injury



11:00-11:15 *Coffee break*

11:15-11:30 **Isabelle Seidita** (University of Florence, IT)
Sphingosine-1-phosphate acts as a pro-inflammatory cue in human endometrial stromal cells acting via ERK5: implication in endometriosis

11:30-11:45 **Zoltan Benyo** (Semmelweis University, HU)
Identification of signaling pathways mediating coronary flow reduction induced by sphingosine-1-phosphate

11:45-12:45 **SESSION 1**
Sphingolipids in health and disease (II)
Chairs: **Lauren Ashley Cowart** (Richmond, US)
Philippe Guerre (Toulouse, FR)

11:45-12:00 **Valentine Yolander** (Virginia Commonwealth University, US)
Sphingosine kinase 1 and sphingosine-1-phosphate receptor function in adipocyte beiging


12:00-12:15 **José Fernandez-Checa** (University of Barcelona, ES)
Dietary and genetic disruption of hepatic methionine metabolism induces acid sphingomyelinase expression to promote steatohepatitis

12:15-12:30 **David Montefusco** (Virginia Commonwealth University, US)
SPTLC3 and atypical sphingolipids as regulators of hepatic glucose production

12:30-12:45 **Mariana Nikolova-Karakashian** (University of Kentucky, US)
Role of neutral sphingomyelinase 2 in fatty liver disease and insulin resistance

12:45-14:20 *Lunch*

- 
- 14:20-15:55 **SESSION 1**
Sphingolipids in health and disease (III)
Chairs: **Thierry Levade** (Toulouse, FR)
Chiara Donati (Florence, IT)
- 14:20-14:45 **Diego Centonze** (IRCCS Neuromed and University of Rome Tor Vergata, IT)
Inflammatory synaptopathy as a novel target of S1P
receptor modulation in experimental multiple sclerosis
- 14:45-15:00 **Mirek Machala** (Veterinary Research Institute, CZ)
Sphingolipid and glycosphingolipid profiles are
altered during benzo[a]pyrene-induced epithelial-
mesenchymal transition of normal human bronchial
epithelial cells, as well as in their exosomes
- 15:00-15:25 **Andrea Huwiler** (University of Bern, CH)
The role of Sphingosine kinase 2 in chronic kidney
disease
- 15:25-15:40 **Christiane Mühle** (University of Erlangen DE)
COVID-19 and its clinical severity are associated
with alterations of plasma sphingolipids and enzyme
activities of sphingomyelinase and ceramidase
- 15:40-15:55 **Trushnal Waghmare** (University of Würzburg, DE)
Role of neutral sphingomyelinase 2 and sialophorin as
virus effector in T cells
- 15:55-17:20 **SESSION 2**
Sphingolipids and malignant diseases (I)
Chairs: **Christiane Mühle** (Erlangen, DE)
Michele Dei Cas (Milan, IT)
- 15:55 -16:20 **Marco Presta** (University of Brescia, IT)
Beta-Galactosylceramidase: more than a psychosine
scavenger




- 16:20-16:35 **Hui-Ming Lin** (Garvan Institute of Medical Research, AU)
Modulation of circulating sphingolipids in metastatic prostate cancer by simvastatin
- 16:35-16:50 *Coffee break*
- 16:50-17:05 **Giovanna Chiorino** (Fondazione Edo ed Elvo Tempia, Biella, IT)
Targeted sphingolipid analysis to improve prostate cancer detection
- 17:05-17:20 **Lorry Carrié** (Université Toulouse III Paul-Sabatier, FR)
Tumor cell-derived sphingosine 1-phosphate promotes loss of adhesion to keratinocytes and contributes to primary melanoma invasion
- 17:20-18:35 **SESSION 2**
Sphingolipids and malignant diseases (II)
Chairs: **Gehriid Van Echten-Deckert** (Bonn, DE)
Angel Gaudio (Madrid, ES)
- 17:20-17:35 **Carine Dufau** (Université de Toulouse III Paul-Sabatier, FR)
Role of ceramide metabolism in TNF-induced melanoma dedifferentiation
- 17:35-17:50 **Davide Capoferri** (University of Brescia, IT)
Beta-galactosylceramidase modulates the pro-oncogenic features of melanoma cells
- 17:50-18:05 **Chiara Raggi** (University of Florence, IT)
Irregular glycosphingolipid patterns in human cholangiocarcinoma stem-like subsets
- 18:05-18:20 **Francois Paris** (Université de Nantes, FR)
Release of ceramide by irradiated endothelial cell inhibits tumor cell proliferation after repression of

Lamin B1 expression

18:20-18:35 **Sumaiya Afsar** (University of Bonn, DE)
SGPL1 ablation affects glucose metabolism in a way
that abets oncogenesis

20:30 *Dinner*





SPHINGOLIPID CLUB

SPHINGOLIPID CLUB

Via Eugubina 66/I - 06126 Perugia (PG)
info@sphingolipidclub.com

WEB SITE



Neuromed Research Centre - Parco Tecnologico
Via dell'Elettronica - 86077 Pozzilli (IS) - Italy
Tel. +39 0865.915204 - Fax +39 0865.927575
direzionescientifica@neuromed.it

LOCATION

